Reuters logo
BRIEF-Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark
October 16, 2017 / 10:16 AM / a month ago

BRIEF-Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark

Oct 16 (Reuters) - Fennec Pharmaceuticals Inc

* Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting

* Fennec Pharmaceuticals Inc - ‍study met primary endpoint​

* Fennec - ‍significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with standard risk hepatoblastoma​

* Says ‍treatment was well tolerated and acute toxicity similar and expected between arms​

* Fennec Pharmaceuticals Inc - ‍company plans to pursue regulatory approvals with FDA and EMA​

* Fennec Pharmaceuticals Inc - co also reported top-line data for secondary endpoints EFS and OS, combination of CIS+STS was generally well tolerated‍​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below